Trial Profile
A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Efizonerimod-alfa (Primary) ; Durvalumab
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors MedImmune
- 12 Mar 2019 Status changed from active, no longer recruiting to completed.
- 20 Jun 2016 Planned number of patients changed from 224 to 39.
- 20 Jun 2016 Status changed from recruiting to active, no longer recruiting.